Search Results - "Uaesoontrachoon, K"

Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage by Barfield, Whitney L, Uaesoontrachoon, Kitipong, Wu, Chung-Sheih, Lin, Stephen, Chen, Yue, Wang, Paul C, Kanaan, Yasmine, Bond, Vernon, Hoffman, Eric P

“…A promoter polymorphism of the osteopontin (OPN) gene (rs28357094) has been associated with multiple inflammatory states, severity of Duchenne muscular…”
Get full text

Protease-activated receptors in the musculoskeletal system by Mackie, E.J., Loh, L.-H., Sivagurunathan, S., Uaesoontrachoon, K., Yoo, H.-J., Wong, D., Georgy, S.R., Pagel, C.N.

“…Protease-activated receptors (PARs) mediate cellular responses to a subset of extracellular proteases, including blood coagulation factors and proteases…”
Get full text

P.11.3 Long term treatment with naproxcinod significantly improves skeletal and cardiac function in mdx mouse model of dystrophy by Nagaraju, K, Uaesoontrachoon, K, Quinn, J, Tatem, K, Creeden, B, Vandermeulen, J, Yu, Q, Gordish, H, Ongini, E, Miglietta, D

“…There is evidence that nitric oxide (NO) plays a critical role in skeletal muscle. In Duchenne muscular dystrophy (DMD) patients and the mdx mouse model of…”
Get full text

290P Developing a non-invasive, in vivo method for evaluating muscle inflammation longitudinally in two mouse models of Duchenne muscular dystrophy by MacKinnon, A., Rowsell, J., Uaesoontrachoon, K., Mullen, A., Hoffman, E., Nagaraju, K.

“…Muscle inflammation, a key characteristic of Duchenne muscular dystrophy (DMD), is replicated in dystrophin deficient mdx mice, making the model ideal for…”
Get full text

P32 Jak inhibitors Tofacitinib and Ruxolitinib do not improve functional deficits in dystrophin-deficient mdx mice by Bosco, C., Uaesoontrachoon, K., Srinivassane, S., Rowsell, J., Elustondo, P., Mackinnon, A., Nagaraju, K., Peterson, J.

“…Repurposing FDA approved drugs is a time and cost-effective strategy for finding potential Duchenne muscular dystrophy (DMD) treatments. Janus Kinase (JAK)…”
Get full text

DMD – ANIMAL MODELS & PRECLINICAL TREATMENT by Gordish-Dressman, H., Uaesoontrachoon, K., Mackinnon, A., Mullen, A., Hoffman, E., Nagaraju, K.

Get full text

DMD – ANIMAL MODELS & PRECLINICAL TREATMENT: P.217 Enhancing the rigor and reproducibility of preclinical efficacy drug trials for DMD using reduced number of wild type and mdx control mice by Gordish-Dressman, H., Uaesoontrachoon, K., Mackinnon, A., Mullen, A., Hoffman, E., Nagaraju, K.

Get full text

Success of preclinical drug trials using reliable and reproducible endpoints in mouse models of neuromuscular diseases by Nagaraju, K., Mullen, A., MacKinnon, A., Uaesoontrachoon, K., Hoffman, E., Srinivassane, S.

Get full text

P.309 - Success of preclinical drug trials using reliable and reproducible endpoints in mouse models of neuromuscular diseases by Nagaraju, K., Mullen, A., MacKinnon, A., Uaesoontrachoon, K., Hoffman, E., Srinivassane, S.

Get full text

Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy by Uaesoontrachoon, Kitipong, Quinn, James L, Tatem, Kathleen S, Van Der Meulen, Jack H, Yu, Qing, Phadke, Aditi, Miller, Brittany K, Gordish-Dressman, Heather, Ongini, Ennio, Miglietta, Daniela, Nagaraju, Kanneboyina

“…In Duchenne muscular dystrophy (DMD) patients and the mouse model of DMD, mdx, dystrophin deficiency causes a decrease and mislocalization of muscle-specific…”
Get full text

REGISTRIES AND CARE OF NEUROMUSCULAR DISORDERS by Mullen, A., Uaesoontrachoon, K., Srinivassane, S., Moraca, M., Ross, W., MacKinnon, A., Bell, C., Gillis, E., Rowsell, J., Malbasic, M., Barkhouse, M., Warford, J., Shala, D., Hoffman, E., Nagaraju, K.

Get full text

REGISTRIES AND CARE OF NEUROMUSCULAR DISORDERS: P.297Treatment responsive outcome measures in mouse models of neuromuscular disease by Mullen, A., Uaesoontrachoon, K., Srinivassane, S., Moraca, M., Ross, W., MacKinnon, A., Bell, C., Gillis, E., Rowsell, J., Malbasic, M., Barkhouse, M., Warford, J., Shala, D., Hoffman, E., Nagaraju, K.

Get full text

VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice by Damsker, Jesse M, Dillingham, Blythe C, Rose, Mary C, Balsley, Molly A, Heier, Christopher R, Watson, Alan M, Stemmy, Erik J, Jurjus, Roslyn A, Huynh, Tony, Tatem, Kathleen, Uaesoontrachoon, Kitipong, Berry, Dana M, Benton, Angela S, Freishtat, Robert J, Hoffman, Eric P, McCall, John M, Gordish-Dressman, Heather, Constant, Stephanie L, Reeves, Erica K M, Nagaraju, Kanneboyina

“…Asthma is a chronic inflammatory condition of the lower respiratory tract associated with airway hyperreactivity and mucus obstruction in which a majority of…”
Get full text